Wall Street brokerages expect Natera, Inc. (NASDAQ:NTRA) to announce $56.73 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Natera’s earnings. The lowest sales estimate is $54.40 million and the highest is $59.06 million. Natera posted sales of $53.89 million in the same quarter last year, which suggests a positive year over year growth rate of 5.3%. The company is scheduled to report its next quarterly earnings report on Wednesday, November 8th.

According to Zacks, analysts expect that Natera will report full-year sales of $56.73 million for the current fiscal year, with estimates ranging from $214.00 million to $223.13 million. For the next year, analysts forecast that the firm will report sales of $282.09 million per share, with estimates ranging from $271.70 million to $288.81 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for Natera.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, August 8th. The medical research company reported ($0.52) earnings per share for the quarter, meeting the consensus estimate of ($0.52). Natera had a negative net margin of 62.64% and a negative return on equity of 137.46%. The business had revenue of $53.60 million during the quarter, compared to analysts’ expectations of $50.57 million. During the same quarter in the prior year, the company posted ($0.46) EPS. The business’s revenue for the quarter was up 3.1% on a year-over-year basis.

A number of research firms recently issued reports on NTRA. Morgan Stanley restated an “overweight” rating and issued a $16.00 target price (up from $13.00) on shares of Natera in a report on Friday, October 6th. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “buy” rating and set a $15.00 target price for the company in a report on Wednesday, October 11th. Cowen and Company restated a “buy” rating and issued a $14.00 target price on shares of Natera in a report on Friday, September 1st. BidaskClub upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, August 23rd. Finally, ValuEngine upgraded shares of Natera from a “strong sell” rating to a “sell” rating in a report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $16.20.

TRADEMARK VIOLATION WARNING: “Zacks: Brokerages Anticipate Natera, Inc. (NTRA) Will Post Quarterly Sales of $56.73 Million” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/18/zacks-brokerages-anticipate-natera-inc-ntra-will-post-quarterly-sales-of-56-73-million.html.

In related news, insider Jonathan Sheena sold 120,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $12.54, for a total value of $1,504,800.00. Following the completion of the sale, the insider now directly owns 533,208 shares in the company, valued at $6,686,428.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 12.57% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Virtu KCG Holdings LLC purchased a new stake in Natera in the second quarter valued at approximately $126,000. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Natera during the second quarter valued at approximately $151,000. Voya Investment Management LLC lifted its position in Natera by 17.8% during the second quarter. Voya Investment Management LLC now owns 14,663 shares of the medical research company’s stock valued at $159,000 after buying an additional 2,212 shares in the last quarter. American International Group Inc. lifted its position in Natera by 7.1% during the first quarter. American International Group Inc. now owns 16,065 shares of the medical research company’s stock valued at $142,000 after buying an additional 1,068 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Natera by 1.2% during the first quarter. Massachusetts Financial Services Co. MA now owns 16,118 shares of the medical research company’s stock valued at $143,000 after buying an additional 194 shares in the last quarter. Hedge funds and other institutional investors own 59.79% of the company’s stock.

Natera (NASDAQ NTRA) opened at 12.99 on Wednesday. The stock has a 50 day moving average of $13.07 and a 200 day moving average of $13.07. The firm’s market capitalization is $691.37 million. Natera has a one year low of $7.35 and a one year high of $14.76.

About Natera

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Natera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera Inc. and related stocks with our FREE daily email newsletter.